PT  - JOURNAL ARTICLE
AU  - Mills, Emma G.
AU  - Smith, Alexander B.
AU  - Griffith, Marissa P.
AU  - Hewlett, Katharine
AU  - Pless, Lora
AU  - Sundermann, Alexander J.
AU  - Harrison, Lee H.
AU  - Zackular, Joseph P.
AU  - Van Tyne, Daria
TI  - Bacteriocin production facilitates nosocomial emergence of vancomycin-resistant <em>Enterococcus faecium</em>
AID  - 10.1101/2024.08.01.24311290
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.08.01.24311290
4099  - http://medrxiv.org/content/early/2024/08/03/2024.08.01.24311290.short
4100  - http://medrxiv.org/content/early/2024/08/03/2024.08.01.24311290.full
AB  - Vancomycin-resistant Enterococcus faecium (VREfm) is a prevalent healthcare-acquired pathogen. Gastrointestinal colonization can lead to difficult-to-treat bloodstream infections with high mortality rates. Prior studies have investigated VREfm population structure within healthcare centers. However, little is known about how and why hospital-adapted VREfm populations change over time. We sequenced 710 healthcare-associated VREfm clinical isolates from 2017-2022 from a large tertiary care center as part of the Enhanced Detection System for Healthcare-Associated Transmission (EDS-HAT) program. Although the VREfm population in our center was polyclonal, 46% of isolates formed genetically related clusters, suggesting a high transmission rate. We compared our collection to 15,631 publicly available VREfm genomes spanning 20 years. Our findings describe a drastic shift in lineage replacement within nosocomial VREfm populations at both the local and global level. Functional and genomic analysis revealed, antimicrobial peptide, bacteriocin T8 may be a driving feature of strain emergence and persistence in the hospital setting.Summary This study shows local and global lineage replacement of vancomycin-resistant Enterococcus faecium. Bacteriocin T8 is enriched in emergent lineages and provides a strong competitive advantage in vitro and in vivo.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was funded by National Institutes of Health grants R01AI165519 (to DVT), R01AI127472 (to LHH), and R35GM138369 (to JPZ). The funders had no role in study design, data collection and analysis, preparation of the manuscript, or decision to publish.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved in its entirety by the institutional review board at the University of Pittsburgh (STUDY21040126).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesGenomic sequences for all 710 VREfm isolates can be found BioProject PRJNA475751 with accession numbers listed in Supplementary Table 1. All other study data are included in the manuscript and supplementary information.